CD274 and non-small cell lung carcinoma: This characteristic reduces the risk of severe immune-related adverse events (irAEs) (21). A meta-analysis of non-small cell lung cancer (NSCLC) patient data suggests that compared to PD-L1 inhibitor treatment, PD-1 inhibitor treatment may increase the incidence of irAEs, both in terms of any grade and high-grade (3-4 grades) irAEs (22).